Chickenpox vaccine is under clinical development by Beijing Minhai Biotechnology and currently in Phase III for Chicken Pox. According to GlobalData, Phase III drugs for Chicken Pox does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Chickenpox vaccine LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Chickenpox vaccine overview
Varicella vaccine is under development for the prevention of chicken pox infection. The drug candidate is a lyophilized live attenuated vaccine. It is administered through subcutaneous route.
Beijing Minhai Biotechnology overview
Beijing Minhai Biotechnology (Minhai), a subsidiary of Shenzhen Kangtai Biological Products Co Ltd is involved in the research, development, production, and marketing of bacteria and virus vaccine products for infectious diseases. Its product line includes Hib conjugate vaccine, DTaP-Hib vaccine, MR vaccine and 23 valent PPSV vaccine. The company’s pipeline products comprise valent PCV, HDCV rabies vaccine, sabin IPV and PENTA among others, which are in pre-clinical trial to New Drug Application (NDA). The company supplies its products through registered distributors across various countries such as Uzbekistan, the Philippines, India, Russia, and Pakistan. Minhai is headquartered in Beijing, China.
For a complete picture of Chickenpox vaccine’s drug-specific PTSR and LoA scores, buy the report here.